Meeting NewsVideo

VIDEO: Speaker discusses targeted treatment for melanoma

NEW YORK — Jeffrey A. Sosman, MD, offered updates in the treatment of BRAF V600–mutant melanoma in light of greater use of immunotherapy at HemOnc Today Melanoma and Cutaneous Malignancies.

The MAP kinase pathway is activated in more than 90% of melanomas, according to Sosman, who is co-director of the translational research program and director of the melanoma program at Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Sosman also discussed options for NRAS–mutated melanoma and the role of MEK inhibition.

“MAP kinase needs to be there as any part of therapy, and immune therapy is certainly a component,” he said. “There are some other ways besides CDK4/6 inhibition that are quite interesting and, quite honestly, if immune therapy hadn’t overwhelmed the field, I think there would be a lot of work and trials looking at these as an alternate.”

Reference:

Sosman JA, et al. Current status of MAP kinase targeting for BRAF–mutated melanoma. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Sosman reports consultant roles with Array, Bristol-Myers Squibb and Genentech.

NEW YORK — Jeffrey A. Sosman, MD, offered updates in the treatment of BRAF V600–mutant melanoma in light of greater use of immunotherapy at HemOnc Today Melanoma and Cutaneous Malignancies.

The MAP kinase pathway is activated in more than 90% of melanomas, according to Sosman, who is co-director of the translational research program and director of the melanoma program at Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Sosman also discussed options for NRAS–mutated melanoma and the role of MEK inhibition.

“MAP kinase needs to be there as any part of therapy, and immune therapy is certainly a component,” he said. “There are some other ways besides CDK4/6 inhibition that are quite interesting and, quite honestly, if immune therapy hadn’t overwhelmed the field, I think there would be a lot of work and trials looking at these as an alternate.”

Reference:

Sosman JA, et al. Current status of MAP kinase targeting for BRAF–mutated melanoma. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Sosman reports consultant roles with Array, Bristol-Myers Squibb and Genentech.

    See more from HemOnc Today New York